Evidence map›Paper›PMID 31222839›Full record

ArticleCancer science2019

Identification of candidates for driver oncogenes in scirrhous-type gastric cancer cell lines.

Eirin Sai, Yoshiyuki Miwa, Reina Takeyama, Shinya Kojima, Toshihide Ueno, Masakazu Yashiro, Yasuyuki Seto, Hiroyuki Mano

Abstract read
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Case reports in hematology · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eirin SaiDepartment of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yoshiyuki MiwaDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Reina TakeyamaDepartment of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shinya KojimaDepartment of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Toshihide UenoDepartment of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masakazu YashiroDepartment of Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0001-5743-7228
Yasuyuki SetoDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki ManoDepartment of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4645-0181

Funding

Japan Agency for Medical Research and Development JP17am0001001
6 · The paper itself

Abstract

Scirrhous-type gastric cancer (SGC) is one of the most intractable cancer subtypes in humans, and its therapeutic targets have been rarely identified to date. Exploration of somatic mutations in the SGC genome with the next-generation sequencers has been hampered by markedly increased fibrous tissues. Thus, SGC cell lines may be useful resources for searching for novel oncogenes. Here we have conducted whole exome sequencing and RNA sequencing on 2 SGC cell lines, OCUM-8 and OCUM-9. Interestingly, most of the mutations thus identified have not been reported. In OCUM-8 cells, a novel CD44-IGF1R fusion gene is discovered, the protein product of which ligates the amino-terminus of CD44 to the transmembrane and tyrosine-kinase domains of IGF1R. Furthermore, both CD44 and IGF1R are markedly amplified in the OCUM-8 genome and abundantly expressed. CD44-IGF1R has a transforming ability, and the suppression of its kinase activity leads to rapid cell death of OCUM-8. To the best of our knowledge, this is the first report describing the transforming activity of IGF1R fusion genes. However, OCUM-9 seems to possess multiple oncogenic events in its genome. In particular, a novel BORCS5-ETV6 fusion gene is identified in the OCUM-9 genome. BORCS5-ETV6 possesses oncogenic activity, and suppression of its message partially inhibits cell growth. Prevalence of these novel fusion genes among SGC awaits further investigation, but we validate the significance of cell lines as appropriate reagents for detailed genomic analyses of SGC.

Indexed as

3T3 CellsAdenocarcinoma, ScirrhousAnimalsCell LineCell Line, TumorCell ProliferationHEK293 CellsHumansHyaluronan ReceptorsMembrane ProteinsMiceMutationOncogenesReceptor, IGF Type 1StomachStomach NeoplasmsHyaluronan ReceptorsMembrane ProteinsReceptor, IGF Type 1BORCS5-ETV6CD44-IGF1Rfusion kinasescirrhous-type gastric cancertyrosine kinase inhibitor

Identifiers

PMID31222839
PMCPMC6676123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.